Biogen's (BIIB) potential Alzheimer's disease drug Leqembi has "meaningful advantages" over Eli Lilly's (LLY) Kisunla that could help surpass its rival, RBC Capital Markets said in a note to investors on Friday.
While Kisunla is being developed and tested more quickly, Leqembi's subcutaneous administration and "cleaner safety" could help it gain a significant foothold in a US market with up to 15 million patients and more than $4 billion in sales, the note said.
"At a penetration of 5%, 50/50 market share split with Kisunla, and similar pricing as in early Alzheimer's disease, we estimate this segment could add another $6B in sales in the US alone," the note said.
Two Leqembi studies are expected to produce results in 2028, the note said.
RBC gave Biogen an "outperform" rating with a price target of $213.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.